Clinical Trial Detail

NCT ID NCT03797326
Title Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

ovarian cancer

colorectal cancer

stomach cancer

cholangiocarcinoma

gallbladder cancer

triple-receptor negative breast cancer

glioblastoma multiforme

Advanced Solid Tumor

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.